Skip to content

Short-term Comparative Clinical Outcomes of Acupuncture and Phototherapy in Chronic Generalized Pruritus

Short-term Comparative Clinical Outcomes of Acupuncture and Phototherapy in Chronic Generalized Pruritus: A Prospective Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07451353
Enrollment
90
Registered
2026-03-05
Start date
2025-01-01
Completion date
2025-07-01
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pruritus

Brief summary

Chronic pruritus is a common and challenging condition with limited effective treatment options. This prospective, randomized comparative study aimed to evaluate the short-term clinical efficacy and safety of acupuncture compared with narrow-band UVB phototherapy in patients with chronic generalized pruritus. A total of 90 adult patients were enrolled and treated for one month. Pruritus severity was assessed using the Visual Analogue Scale (VAS) and Investigator's Global Assessment (IGA) at baseline and after treatment.

Detailed description

This prospective comparative study included 90 adult patients diagnosed with chronic generalized pruritus. Participants were randomized into two parallel groups: an acupuncture group (n=50) and a narrow-band UVB phototherapy group (n=40). Acupuncture was administered twice weekly for one month (eight sessions total) using standardized acupuncture points in accordance with STRICTA recommendations. Phototherapy was administered three times weekly for one month. The primary outcomes were changes in pruritus severity measured by VAS and IGA at baseline and at one month. Safety and comparative short-term efficacy were evaluated.

Interventions

DEVICESterile disposable acupuncture needles

Sterile disposable stainless steel acupuncture needles (0.25 × 25 mm) were used for acupuncture treatment.

DEVICENarrow Band UVB Phototherapy Unit

Patients underwent narrow-band UVB phototherapy three times per week for one month. Narrowband UVB therapy was administered using a licensed NB-UVB phototherapy unit. Treatment doses ranged between 3.6 and 5.34 J/cm², adjusted according to individual skin type.

Sponsors

Ankara University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Clinical diagnosis of chronic generalized pruritus lasting longer than 6 weeks * Ability to understand the study procedures and provide written informed consent * Willingness to comply with the study protocol and attend scheduled visits

Exclusion criteria

(Acupuncture Group): * Pregnancy or breastfeeding * Bleeding disorders or use of anticoagulant therapy * Skin diseases or lesions impairing skin integrity at acupuncture application sites * Advanced hypertension or heart failure

Design outcomes

Primary

MeasureTime frameDescription
Change in Visual Analogue Scale for PruritusBaseline to 1 monthThe Visual Analogue Scale (VAS) is a patient-reported scale used to assess pruritus severity. Unit of Measure: Units on a Scale Scale Description : Visual Analogue Scale ranges from 0 to 10, where 0 indicates no pruritus and 10 indicates the worst imaginable pruritus. Higher scores indicate worse pruritus severity.

Secondary

MeasureTime frameDescription
Change in Investigator's Global Assessment for Chronic PruritusBaseline to 1 monthInvestigator's Global Assessment (IGA) is a clinician-rated scale assessing disease severity in patients with chronic pruritus. Unit of Measure: Units on a Scale Scale Description: Investigator's Global Assessment scores range from 0 to 4, where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe disease. Higher scores indicate worse disease severity.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 19, 2026